



IMMERSE

Implementing Mobile MEntal health Recording Strategy for Europe

H2020 - 945263

D 8.1	Exploitations Steering Committee Charter
Dissemination level¹	CO
Contractual date of delivery	31/7/21
Actual date of delivery	2/7/21
Type²	Report
Work package	8
Work package lead	Inez Myin-Germeys

Author list

Organisation	Name	Contact information
P1 – KU Leuven	Inez Myin-Germeys	Inez.germeys@kuleuven.be

Document history

Version	Date
1	2/7/21

¹ Please choose the appropriate reference:

PU = Public, fully open, e.g. web;

CO = Confidential, restricted under conditions set out in Model Grant Agreement;

CI = Classified, information as referred to in Commission Decision 2001/844/EC.

² Use one of the following codes:

R: Document, report (excluding the periodic and final reports)

DEM: Demonstrator, pilot, prototype, plan designs

DEC: Websites, patents filing, press & media actions, videos, etc.

OTHER: Software, technical diagram, etc



Table of contents

1. Summary.....	3
2. Deliverable report.....	3
2.1 Mission.....	3
2.2 Tasks.....	3
2.3 Members and governance structure.....	5
2.4 Operational aspects.....	5



1. Summary

This WP sets up and orchestrates the activities of the Exploitation Steering Group (ESG; further described in section 2.2.1.2.) in order to continuously update and refine the exploitation of IP. At M4 the charter will be established.

2. Deliverable report *D 8.1. Exploitation Steering Group Charter*

2.1 Mission

The mission of the Exploitation steering group (ESG) is to aid the IMMERSE consortium in working towards successful innovation management, in order to create a sustainable environment for boosting the consortium's future scientific and venture projects on the EU healthcare markets. The ESG will serve as a strategic board that particularly focuses on developing strategies for valorisation, exploitation and successful technology transfer of the solutions developed in the IMMERSE consortium.

The ESG will set the IPR strategy, track IP, and adapt the IPR strategy throughout the project. The ESG will also further develop the dissemination and exploitation plan. The ESG will meet quarterly to set and evaluate a roadmap for valorisation and exploitation of all tangible and intangible research assets of IMMERSE.

2.2 Tasks

The design of an efficient and profitable exploitation strategy that centers on:

1) the **protection of intellectual property rights (IPR)**, that can be divided into **open innovation outputs** of the IMMERSE project and the **proprietary tangible and intangible assets** as follows:

i) Open innovation outputs: in keeping with the open innovation framework, the vast majority of research assets and knowledge generated as part of IMMERSE will be disseminated in the following open repositories:

- **All scientific impact-creating advances:** Open Science Framework pre-registrations, registered reports, open-access peer-reviewed journals, IMMERSE website, conference proceedings.
- **Dynamic modeling and predictive algorithms):** GitHub, links on the IMMERSE website
- **Interoperability specifications:** Github, provision of FHIR implementation guide to the HL7 community

ii) Proprietary assets: *the source-code of the DMMH developed by the SME partner* constitutes a significant innovation for the healthcare market that can be exploited to ensure



transfer, further scale-up and long-term sustainability of the DMMH and growth of the industry partner (figure 1).




Figure 1

2) **Track IP**, including advice on the development of the technology transfer package (IP portfolio), creating transparent conditions for new IP developed based on project findings, as well as **adapt the IPR strategy** throughout the project.

3) Strategic advice on the **development of several exploitation pathways**. This will include a market analysis and analysis of the competitor landscape, as well as a view on policy changes and global and local trends. This would then lead to potential exploitation paths, including:

- i) **exploit the software components** developed by Movisens during the project for the DMMH and license them as a stand-alone medical product to companies and hospitals;
- ii) **exploit the newly developed software** included into the TherapyBuilder base components, and offer them on a fee-for-service basis to researchers and clinicians interested in the generation of novel DMMH systems to be further validated and certified in clinical studies;
- iii) **exploit the document templates that will be generated and extended for the lifecycle process** during the IMMERSE project as part of a fee-for-service consulting that movisens will offer to other researchers, companies and actors in the industry



2.3 Members and Governance Structure

The Exploitation Steering Group has been set up, and includes representatives of the relevant WP's including the technology WP (WP2), the data management and interoperability WP (WP3), the WP on modeling (WP4), the regulatory WP (WP6), and representatives of the clinical WP's (WP7) as well as the valorisation WP (WP8). Someone from of Leuven Research and Development will take part as an adviser but will not be a formal member of the ESG. The ESG will be led by the project management team (the PI and the project manager).

Inez Myin-Germeys (WP1 – Coordinator – 1.KU LEUVEN)

Martine van Nierop (WP1 – Project Manager – 1.KU LEUVEN)

Simon Krause (WP 2 – 8.Movisens)

Joerg Ottenbacher (WP2 – 8.Movisens)

Thomas Ganslandt (WP 3 – 6.UHEI)

Georgia Koppe (WP4 – 2.CIMH)

Luca Marelli (WP 6 – 1.KU LEUVEN)

Ulrich Reininghaus (WP7 – 2.CIMH)

Anton Heretik (WP7 – 4.UK BA)

Iveta Nagyova (WP7 – 5.UPJS)

Matthias Schwannauer (WP7 – 3.UEDIN)

Evelyne van Aubel (WP8 – 1.KU Leuven)

The ESG will work according to the guidelines outlined in the Grant and Consortium Agreement.

2.4 Operational aspects

The ESG will meet quarterly in an online meeting to set up and evaluate the roadmap for valorisation and exploitation of all tangible and intangible research assets of IMMERSE.

